Technical Analysis for PPBT - Purple Biotech Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 3.11 | -3.12% | -0.10 |
Earnings due: Nov 19
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | -3.12% | |
NR7 | Range Contraction | -3.12% | |
NR7-2 | Range Contraction | -3.12% | |
Narrow Range Bar | Range Contraction | -3.12% |
Alert | Time |
---|---|
Down 5% | about 21 hours ago |
Fell Below Lower Bollinger Band | about 21 hours ago |
New 52 Week Low | about 21 hours ago |
Possible NR7 | about 22 hours ago |
60 Minute Opening Range Breakdown | 1 day ago |
Get a Trading Assistant
- Earnings date: 11/19/2024
Purple Biotech Ltd. Description
Purple Biotech Ltd. (f/k/a Kitov Pharma Ltd.) (the “Company”; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) in a phase 1/2 study. CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. The Company plans to advance CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company’s U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company is relocating its corporate headquarters imminently to Rehovot, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Cancer Treatment Tumor FDA Hypertension Non Small Cell Lung Cancer Antineoplastic Drugs Pancreatic Cancer Lung Cancer Breakthrough Therapy Osteoarthritis Advanced Solid Tumors Checkpoint Inhibitor Non Small Cell Lung Carcinoma Novel Cancer Treatment Of Non Small Cell Lung Cancer Treatment Of Osteoarthritis Health Effects Of Tobacco Pd 1 Programmed Cell Death Protein 1
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 25.8 |
52 Week Low | 3.0 |
Average Volume | 36,238 |
200-Day Moving Average | 10.11 |
50-Day Moving Average | 6.03 |
20-Day Moving Average | 4.04 |
10-Day Moving Average | 3.86 |
Average True Range | 0.57 |
RSI (14) | 27.54 |
ADX | 58.08 |
+DI | 8.00 |
-DI | 32.00 |
Chandelier Exit (Long, 3 ATRs) | 4.22 |
Chandelier Exit (Short, 3 ATRs) | 4.70 |
Upper Bollinger Bands | 5.08 |
Lower Bollinger Band | 3.00 |
Percent B (%b) | 0.05 |
BandWidth | 51.28 |
MACD Line | -0.70 |
MACD Signal Line | -0.69 |
MACD Histogram | -0.0169 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.74 | ||||
Resistance 3 (R3) | 3.77 | 3.60 | 3.64 | ||
Resistance 2 (R2) | 3.60 | 3.44 | 3.58 | 3.60 | |
Resistance 1 (R1) | 3.35 | 3.34 | 3.27 | 3.32 | 3.56 |
Pivot Point | 3.18 | 3.18 | 3.13 | 3.16 | 3.18 |
Support 1 (S1) | 2.93 | 3.02 | 2.85 | 2.90 | 2.66 |
Support 2 (S2) | 2.76 | 2.92 | 2.74 | 2.62 | |
Support 3 (S3) | 2.51 | 2.76 | 2.59 | ||
Support 4 (S4) | 2.48 |